ClinicalTrials.gg
CompletedNCT01408433Updated Mar 26, 2015

Single Embryo Transfer of a Euploid Embryo Versus Double Embryo Transfer

An interventional study of Single Embryo Transfer and Double embryo transfer in Infertility, sponsored by Reproductive Medicine Associates of New Jersey. Completed at 2 sites in United States. Open to participants aged 18 Years to 43 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-26.

Sponsored by Reproductive Medicine Associates of New Jersey · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 43 Years
Sex
All
01

Study summary

This study seeks to compare the pregnancy and delivery rates of patients who undergo a single embryo transfer, when the embryo has been tested and determined to be chromosomally normal, with pregnancy and delivery rates of patients who undergo a two (2) embryo transfer of untested embryos.

Read the detailed description

This study will recruit patients from the NJ/NY/CT/eastern PA area only.

Twin and higher-order multiple pregnancies are the most common and most significant complication of pregnancies conceived through assisted reproductive technologies (ART). Twin rates in in vitro fertilization (IVF) cycles are approximately 30%. These pregnancies have increased complications for both the mother and the babies. A singleton, one baby, is the safest outcome for an IVF cycle. The surest way to reduce the risk of multiple births in IVF cycles is to transfer fewer embryos. Prior studies on single embryo transfer (SET) have shown decreased pregnancy rates because of the difficulty in selecting which embryo to transfer. Being chromosomally normal is necessary for the delivery of a healthy baby. The investigators are now able to screen all 24 chromosomes of an embryo with greater than 97% accuracy within four hours, allowing for a fresh embryo transfer of a tested embryo, using Comprehensive Chromosome Screening (CCS). This study seeks to show that the transfer of a single CCS-normal embryo will result in delivery rates equal to those resulting from a two embryo transfer, the current standard of care in IVF.

Patients will undergo IVF according to the protocol recommended by their primary doctor. On the day of egg retrieval, all mature eggs will be fertilized by intracytoplasmic sperm injection (ICSI) per routine laboratory protocol. Embryos will then be cultured out to day 5 per routine laboratory procedure. The embryos will be assessed by the embryologist on day 5 to determine if the patient is a candidate for a fresh transfer. Patients who are a candidate for fresh transfer will be randomized into either the single embryo transfer of a chromosomally normal embryo group or the double, untested embryo group. Patients will have a 50:50 chance of being in the single or double embryo transfer group. Embryos in the single embryo group will undergo biopsy for CCS and patients will then undergo transfer of the morphologically best, chromosomally normal embryo. Additional embryos will be cryopreserved. Patients in the double embryo transfer group will undergo a two embryo transfer. Additional embryos will be cryopreserved. If patients are not a candidate for a fresh transfer (potentially because of endometrial lining development, risk of ovarian hyperstimulation syndrome, or embryos that are not suitable for biopsy on day 5), they will still be randomized into either the single or double embryo transfer group. Patients in the single embryo transfer group will have all embryos biopsied for CCS prior to being frozen. Patients will then immediately undergo a synthetic frozen embryo transfer cycle in accordance with their randomization. Patients in the double embryo transfer group will have their embryos frozen and will then immediately prepare for a synthetic frozen embryo transfer cycle in accordance with their randomization. Any patient who does not become pregnant during their fresh transfer cycle will immediately undergo a synthetic frozen embryo transfer cycle in accordance with their original randomization.

All clinical follow up will be per routine regarding pregnancy testing, early pregnancy monitoring and subsequent transfer of care to the patient's obstetrician. If clinical miscarriage occurs, cells from the products of conception will be collected, if possible, and submitted for genetic analysis. If the pregnancy progresses to delivery, a buccal swab (small swab touched to the inside of the baby's cheek) will be collected and submitted for genetic analysis.

02

Conditions studied

  • Infertility

Browse trials for

Keywords

  • embryo transfer
  • in-vitro fertilization (IVF)
  • pre-implantation diagnosis (PGD)
  • infertility
  • single embryo transfer
  • two embryo transfer
  • double embryo transfer
03

In context

Infertility

2,541 studies on the registry are indexed under Infertility; 405 are open to participants now.

This study's enrollment of 175 is above the median of 120 across 1,722 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Reproductive Medicine Associates of New Jersey is the lead sponsor of 55 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 43 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Maximum of one (1) prior failed IVF cycle (a failed cycle is any cycle that did not deliver. Pregnancy losses are failed cycles. Ok to participate as a recipient in an egg donor cycle.)
  2. Female partner less than 43 years old at time of onset of IVF cycle
  3. Maximum prior day 3 follicle stimulation hormone (FSH) level of 12 (in RMA NJ laboratory)
  4. Minimum anti-mullerian hormone (AMH)of 1.2 within 1 year
  5. Normal uterine cavity demonstrated by saline sonogram, hysterosalpingogram or hysteroscopy within 1 year.
  6. Male partner with greater than 100,000 total motile spermatozoa. Donor sperm ok.
  7. Body Mass Index (BMI) less than or equal to 30 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of chronic anovulation (cycles typically longer than 90 days)
  2. Diagnosis of endometrial insufficiency- prior cycle with endometrial thickness less than 6mm, abnormal endometrial echotexture, persistent endometrial fluid.
  3. Clinical indication of aneuploidy screening (i.e. history of loss of chromosomally abnormal pregnancies)
  4. Clinical indication for PGD for single-gene disorder (i.e. PGD is needed to select against the transfer of embryos affected with a specific condition)
  5. Use of testicular aspiration or biopsy procedures to obtain sperm
  6. Unevaluated ovarian mass or surgically confirmed stage IV endometriosis
  7. Presence of hydrosalpinges which communicate with the endometrial cavity
  8. Any contraindication to undergoing in vitro fertilization
05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Other
    Single Embryo Transfer

    Patients will have a single, chromosomally normal embryo transferred.

    Other: Single Embryo Transfer

  • Other
    Double Embryo Transfer

    Patients will have two (2) untested embryos transferred.

    Other: Double embryo transfer

Interventions

  • OtherSingle Embryo Transfer

    single embryo transfer of a chromosomally normal embryo

    Also known as: pre-implantation genetic diagnosis (PGD), in-vitro fertilization (IVF)

  • OtherDouble embryo transfer

    two (2) embryo transfer of untested embryos

    Also known as: two embryo transfer, in-vitro fertilization (IVF)

06

What researchers measure

Primary outcomes

  1. Live birth rate per randomized patient (single embryo transfer vs. 2 embryo transfer)

    Compare live birth rates of patients who have a single embryo transfer of a chromosomally normal embryo with the live birth rates of patients who have two, untested embyros transferred.

    Time frame: 2 years

Secondary outcomes

  1. Twin live birth rate

    Compare twin live birth rates of patients who have a single embryo transfer of a chromosomally normal embryo with the twin live birth rates of patients who have two, untested embryos transferred.

    Time frame: 2 years

  2. Sustained implantation rate (number of viable fetuses beyond the first trimester per embryo transferred)

    Compare sustained implantation rates of patients who have a single embryo transfer of a chromosomally normal embryo with the sustained implantation rates of patients who have two, untested embryos transferred.

    Time frame: 2 years

  3. Live birth rate per embryo transfer

    Compare live birth rates per transfer of patients who have a single embryo transfer of a chromosomally normal embryo with the live birth rates per transfer of patients who have two, untested embryos transferred.

    Time frame: 2 years

07

Study locations

2 sites
  • Reproductive Medicine Associated of New Jersey
    Morristown, New Jersey 07960, United States
  • Reproductive Medicine Associated of Pennsylvania at lehigh Valley
    Allentown, Pennsylvania 18104, United States
08

References and documents

Publications

  • Forman EJ, Hong KH, Ferry KM, Tao X, Taylor D, Levy B, Treff NR, Scott RT Jr. In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial. Fertil Steril. 2013 Jul;100(1):100-7.e1. doi: 10.1016/j.fertnstert.2013.02.056. Epub 2013 Mar 30. PubMed 23548942 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01408433
Lead sponsor
Reproductive Medicine Associates of New Jersey
Responsible party
Sponsor
First posted
Aug 3, 2011
Start date
Aug 2011
Primary completion
Jul 2013
Completion
Dec 2014
Last update
Mar 26, 2015

Study contacts

Richard T Scott, MD
principal investigator · RMA NJ

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion